Economic Evaluation of Azacitidine in Elderly Patients with Acute Myeloid Leukemia with High Blast Counts

Background Azacitidine is an hypomethylating agent widely adopted for the treatment of acute myeloid leukaemia (AML) in patients who are ineligible for curative-intent chemotherapy. Patients with low bone marrow blast counts ( 30% blasts in the bone marrow. As such, there is uncertainty around the e...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PharmacoEconomics - Open 2020-06, Vol.4 (2), p.297-305
Hauptverfasser:	Coyle, D., Villeneuve, Pierre J. A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute myelocytic leukemia Analysis Antineoplastic agents Azacitidine Bone marrow Cancer treatment Chemotherapy Clinical trials Cost analysis DNA methylation Drug dosages Economic analysis Economic aspects Elderly Elderly patients Explosions Health care expenditures Leukemia Life expectancy Markov processes Medical care quality Medical prognosis Medicine Medicine & Public Health Myelodysplastic syndromes Myeloid leukemia Older people Original Original Research Article Patients Pharmacoeconomics and Health Outcomes Probability Probability distribution Quality of life Remission (Medicine) Stem cell transplantation Third party Time
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!